Výsledky vyhledávání - "Antonieta, Salud"

Akademický článek

MicroRNAs Present in Malignant Pleural Fluid Increase the Migration of Normal Mesothelial Cells In Vitro and May Help Discriminate between Benign and Malignant Effusions

Autor: Marta Marqués, Mariona Pont, Iván Hidalgo, Maria Alba Sorolla, Eva Parisi, Antonieta Salud, Anabel Sorolla, José M. Porcel

Publikováno v: International Journal of Molecular Sciences, Vol 24, Iss 18, p 14022 (2023)

The sensitivity of pleural fluid (PF) analyses for the diagnosis of malignant pleural effusions (MPEs) is low to moderate. Knowledge about the pathobiology and molecular characteristics of this condition is limited. In this study, the crosstalk betwe

Externí odkaz: https://doaj.org/article/3560982020584fecb23b054d560de872

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

PLA2G12A as a Novel Biomarker for Colorectal Cancer with Prognostic Relevance

Autor: Eva Parisi, Ivan Hidalgo, Robert Montal, Ona Pallisé, Jordi Tarragona, Anabel Sorolla, Anna Novell, Kyra Campbell, Maria Alba Sorolla, Andreu Casali, Antonieta Salud

Publikováno v: International Journal of Molecular Sciences, Vol 24, Iss 13, p 10889 (2023)

Metastasis is the leading cause of colorectal cancer (CRC)-related deaths. Therefore, the identification of accurate biomarkers predictive of metastasis is needed to better stratify high-risk patients to provide preferred management and reduce mortal

Externí odkaz: https://doaj.org/article/734f66ba603c4f00bbabd52aaa5a0901

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Selection of neoadjuvant treatment based on the 21-GENE test results in luminal breast cancer

Autor: Serafin Morales Murillo, Ariadna Gasol Cudos, Joel Veas Rodriguez, Carles Canosa Morales, Jordi Melé Olivé, Felip Vilardell Villellas, Douglas Rene Sanchez Guzman, Edelmiro Iglesias Martínez, Antonieta Salud Salvia

Publikováno v: Breast, Vol 56, Iss , Pp 35-41 (2021)

Neoadjuvant chemotherapy (NAC) is an optimal option in early breast cancer, but in ER-positive/HER2-negative (luminal) is still controversial, although a survival benefit has recently been observed when a histological response by Symmans’ method ty

Externí odkaz: https://doaj.org/article/658cf1ccd10c415eaf74240a272fb44b

Zobrazit plný text záznamu

Akademický článek

Survival analysis of bevacizumab plus taxane treatment in luminal metastatic breast cancer

Publikováno v: Future Science OA, Vol 7, Iss 3 (2021)

Background: The treatment of luminal metastatic breast cancer is based on endocrine therapy and chemotherapy treatment is limited to the progression of this treatment. Materials & methods: We analyzed the efficacy of treatment with bevacizumab plus p

Externí odkaz: https://doaj.org/article/614fe8c76d374c33a3ebf26bd6c67b95

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání